Skip to main content
. 2018 Sep 25;9(75):34038–34055. doi: 10.18632/oncotarget.25954

Figure 6. Influence of MAPK inhibitors on the angiogenic capabilities of HUVECs suspended in conditioned media (CM) from cisplatin- or vehicle-treated A549 and H358 cells.

Figure 6

A549 and H358 cells were preincubated with vehicle, the p38 MAPK inhibitor, SB203580, or the inhibitor of p42/44 MAPK activation, PD98059, (10 µM each) for 1 h. Subsequently, cells were treated with vehicle or 1 µM cisplatin for 48 h prior to the collection of CM for the analysis of TIMP-1 (B and D) or for the preparation of HUVEC suspension that was subsequently subjected to the upper chamber for quantification of migration following a further 24-h incubation (A and C). Western blotting images are representative of each experiment. Values above the blots are the mean ± SEM and represent alterations in TIMP-1 protein levels in CM in comparison with vehicle-treated cells (set as 100%), according to densitometric analyses. Western blotting analysis of TIMP-1 in CM was supplemented with β-actin analysis of the respective cell lysates. Values are the mean ± SEM of n = 4 except of n = 3 in (D), left. *p < 0.05, ***p < 0.001 vs. corresponding vehicle control; ### p < 0.001 vs. the respective cisplatin-treated group, one-way ANOVA plus a post-hoc Bonferroni test.